Clinical Trial Applications: Filter, Search, and view applications
| # | Protocol No | Study Title | Investigator(s) & Site(s) | |
|---|---|---|---|---|
391. |
ECCT/22/03/06 | Sickle Cell Disease A Phase 2a Randomized, Double-Blind, Placebo-Controlled Study to Characterize the Pharmacokinetics and Pharmacodynamics of Rifaximin Novel Formulations in Patients with Sickle Cell Disease |
Principal Investigator(s) 1. Janet Oyieko 2. Fredrick Chite Asirwa 3. Bernhards Ogutu Site(s) in Kenya 1. Kombewa Clinical Research Centre (Kisumu county) 2. Victoria Biomedical Research institute (Kisumu county) 3. International Cancer Centre (Uasin Gishu county) 4. CREATES - Strathmore University Medical Centre (Nairobi City county) |
View |
392. |
ECCT/24/03/06 | PHOENIx MDR-TB) Protecting Households On Exposure to Newly Diagnosed Index Multidrug-Resistant Tuberculosis Patients (PHOENIx MDR-TB) |
Principal Investigator(s) 1. Dr Lucy Chepkurui Koech KOECH Site(s) in Kenya 1. Kenya medical Research Institute/ Walter Reed Project (Kericho county) 2. Moi university clinic research Centre (Uasin Gishu county) |
View |
393. |
ECCT/17/06/01 | MF/PM Phase III An Open Label, Phase III, Randomized Controlled, Multicentre Non-Inferiority Trial to Compare Efficacy and Safety of Miltefosine and Paromomycin with Sodium Stibogluconate and Paromomycin Combination for Treatment of Primary Visceral Leishmaniasis (VL) Patients in Eastern Africa |
Principal Investigator(s) 1. Jane Mbui Site(s) in Kenya 1. Kimalel Health Centre (Baringo county) 2. Kacheliba sub-county hospital (West Pokot county) |
View |
394. |
ECCT/19/03/02 | PREVENT TD A Randomized, Placebo-Controlled, Double-Blind, Clinical Trial Evaluating Two Dose Regimens of Rifaximin (550 mg daily or 550 mg twice daily) for Chemoprophylaxis Against Travellers’ Diarrhoea (TD) Among Active Duty Deployed U.S. and British Military Personnel (PREVENT TD) |
Principal Investigator(s) 1. Flynn Alexander Site(s) in Kenya Nyati Barracks, British Army Training Unit, Kenya |
View |
395. |
ECCT/13/04/03 | HIV-Malaria Study_A5297 An Open-Label, Proof of Concept, Randomized Trial Comparing a LPV/r-Based to an nNRTI-Based Antiretroviral Therapy Regimen for Clearance of Plasmodium falciparum Subclinical Parasitemia in HIV-infected Adults with CD4+ Counts >200 and <350 cells/mm3 . |
Principal Investigator(s) 1. Josphat K. Kosgei Site(s) in Kenya 1. Kemri Walter Reed Project-Kericho (Kericho county) 2. Moi University Clinical Research Centre (Uasin Gishu county) |
View |